Invivoscribe is dedicated to improving the quality of healthcare. We currently provide the majority of all DNA- and RNA-based molecular diagnostic reagents for leukemia and lymphoma testing worldwide.

The Media section provides reporters with easy access to Invivoscribe information and also contains our recent and archived press releases.

Current News Highlights

12/26/2011 The New York Times
A Push to Tie New Drugs to Testing by Andrew Pollack

02/23/2011 Pharmacogenomics Reporter
Novartis, Invivoscribe to Develop Companion Test for Acute Myeloid Leukemia Rx Midostaurin

02/21/2011 BioCentury
Invivoscribe Technologies Inc., Novartis deal

View all news

Press Releases

February 15, 2011

Invivoscribe Announces Collaboration Agreement to Develop Companion Diagnostic Test (English) (Chinese) (French) (German) (Korean) (Japanese) (Portuguese) (Russian) (Spanish) (Swedish)

March 2010
TrovaGene, Inc., announces NPM1 testing available through Invivoscribe subsidiary, LabPMM (.pdf)

February 2010
Invivoscribe's subsidiary, LabFlow, announces launch of its proprietary comprehensive ERP software.

View all press releases

Upcoming Events

June 14-17, 2012
17th Congress of EHA, Amsterdam RAI, Amsterdam, The Netherlands

October 25-27, 2012
AMP 2012 Annual Meeting, Long Beach Convention & Entertainment Center, Long Beach, California, USA

December 8-11, 2012
2012 ASH Annual Meeting and Exposition, Georgia World Congress Center, Atlanta, Georgia, USA

Media Inquiries
If you are a member of the media, please contact our Corporate Relations department.
Phone: +1 858 224-6600
Fax: +1 858 224-6601

Email: Corporate Relations

Quick Links
Medical Conditions
Research Focus
Development
Product Information
Views on Public Policy
LabPMM
FLT3 Gene Mutation

Invivoscribe Companies